Please login to the form below

Not currently logged in
Email:
Password:

Spectrum Pharmaceuticals

This page shows the latest Spectrum Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

J&J extends its JLABS incubator scheme to Europe

J&J extends its JLABS incubator scheme to Europe

30 life science start-ups “focused on innovations across the entire healthcare spectrum, including biotech, pharmaceuticals, medical devices, consumer and health tech sectors”.

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    8, 600. Trius Therapeutics / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3). ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology portfolio, Marqibo for leukaemia (FDA

  • Pharma deals during July 2013 Pharma deals during July 2013

    Whilst the Elan and Perrigo deal creates a diversified business, several companies, such as Cubist, Ipsen and Spectrum Pharmaceuticals, focused on acquiring assets to bolster their core business areas in antibiotics, ... Following its $15m investment in

  • Pharma deals during March 2013 Pharma deals during March 2013

    Chinese traditional medicines and Western medicines. 70.5. Ligand Pharmaceuticals/ Spectrum Pharmaceuticals. ... Astellas Pharma/ Cubist Pharmaceuticals ††. Acquisition of rights. Ceftolozane for complicated Gram-negative infections.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics